Hot Low Price Companies For 2014

Robert Olstein (Trades, Portfolio) is the chairman and chief investment officer of the Olstein Financial Alert Fund (OFALX). He is considered to be an expert in corporate financial disclosure and reporting practices.

A description of their investment philosophy can be found here.

Let�� take a look at his top three buys over the last quarter:

AT&T (T): This is a new holding for the fund. Olstein bought 146,000 shares at prices between $33.1 and $36.45. The current stock price is 33.01, i.e. a 5% to the average high-low price over the period. The stock has been in a bear trend for more than a year but counts Gurus James Barrow (Trades, Portfolio) and Brian Rogers (Trades, Portfolio) as biggest holders. AON (AON): The fund purchased 60,000 shares in the insurance company for a 0.75% impact to the portfolio. The stock is still trading at the upper bound of the high-low price ranges over the past quarter. Aon PLC provides risk management and human capital consulting services, delivering distinctive client value via risk management solutions, including insurance and reinsurance brokerage and workforce productivity solutions. It is also noteworthy that the stock saw a large insider buy of more than $2 million by one of the company�� director 10 days ago. International Game Technology (IGT): IGT is a global gaming company specializing in the design, manufacture and marketing of electronic gaming equipment and systems products. The Olstein fund added 246,000 shares of the company over the last quarter. The current price is at a 20% discount to the average of the price range over the period. It is noteworthy that Guru John Hussman (Trades, Portfolio) also bought 500,000 shares over the same period.
Also check out: Robert Olstein Undervalued Stocks Robert Olstein Top Growth Companies Robert Olstein High Yield stocks, and Stocks that Robert Olstein keeps buying

Currently 3.00/512345

Rating: 3.0/5 (2 votes)

5 Best High Tech Stocks To Invest In Right Now: McGraw Hill Financial Inc (MHFI)

McGraw Hill Financial, Inc. incorporated on December 29, 1925, is a financial intelligence company. The Company is engaged in credit ratings, benchmarks and analytics for the global capital and commodity markets. The Company�� brands include Standard & Poor's Ratings Services, S&P Capital IQ, S&P Dow Jones Indices, Platts, CRISIL, J.D. Power & Associates, McGraw Hill Construction and Aviation Week. The Company�� credit ratings, indices, price assessments and other capabilities provide clients with the intelligence to manage risk. Standard & Poor�� Ratings Services helps investors and markets participants measure and manage credit risk through credit ratings, research and analytics. S&P Capital IQ is a provider of real-time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities globally. On March 22, 2013, the Company sold McGraw-Hill Education. Effective July 18, 2013, McGraw Hill Financial Inc acquired a remaining undisclosed interest which it did not already own in Tata McGraw-Hill Education Pvt Ltd from Tata charitable trust. In August 2013, McGraw Hill Financial Inc completed the sale of Aviation Week to Penton.

The Company provides a range of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. The Company�� S&P Dow Jones Indices is the provider of financial market indices. Its Platts is a provider of information and a source of benchmark price assessments for the energy, petrochemicals, metals and agriculture markets. J.D. Power & Associates is a global marketing information services company operating in business sectors, including customer satisfaction research, market research, social media research, and performance improvement programs. McGraw Hill Construction connects people, projects, and products across the design and construction industry. AVIATION WEEK is! the multimedia information and services provider to the global aviation, aerospace and defense industries.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on McGraw Hill Financial (NYSE: MHFI  ) , whose recent revenue and earnings are plotted below.

Hot Low Price Companies For 2014: International Rectifier Corporation (IRF)

International Rectifier Corporation designs, manufactures, and markets power management semiconductors worldwide. The company operates through six segments: Power Management Devices, Energy Saving Products, Automotive Products, Enterprise Power, HiRel, and Intellectual Property. The Power Management Devices segment provides power metal oxide semiconductor field effect transistors (MOSFETs), FETKYs, and DirectFETs for power supply, data processing, telecommunications, industrial, and commercial battery-powered systems. The Energy Saving Products segment provides analog high voltage integrated circuits (HVICs), insulated gate bipolar transistors (IGBTs) platforms, digital control ICs, and IRAM integrated power modules for motor control appliances, industrial automation, lighting and display, audio, and video applications. The Automotive Products segment offers HVICs, intelligent power switch ICs, power MOSFETs, IGBTs, diodes, and advanced power modules for various automotive applications. The Enterprise Power segment offers DirectFET discrete products, digital PWM controllers, power monitoring products, voltage regulators, low voltage ICs, and PowIRstages primarily for applications in servers, storage, routers, switches, infrastructure equipment, notebooks, graphic cards, and gaming consoles. The HiRel segment provides RAD-hard discretes, RAD-hard ICs, power management modules, DC-DC converters, and high temperature converters for satellites and space exploration vehicles, military hardware, and other high reliability applications. The Intellectual Property segment sells and licenses technologies and manufacturing process know-how. The company was founded in 1947 and is headquartered in El Segundo, California.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on International Rectifier (NYSE: IRF  ) , whose recent revenue and earnings are plotted below.

Hot Low Price Companies For 2014: Wasgau Produktions & Handels AG (MSH)

Wasgau Produktions & Handels AG is a Germany-based retailer and producer of food articles. The Company divides its business activities into the two main segments Wholesale and Retail. The Wholesale�� businesses include seven Cash and Carry markets for restaurateurs and wholesale customers, as well as commercial businesses of the holding company WASGAU Produktions & Handels AG, which are supported by its subsidiary WASGAU Dienstleistungs & Logistik GmbH, active within warehouse management and transportation. The Operations within the Retail segment are mainly carried out through Company�� subsidiaries WASGAU Metzgerei GmbH and WASGAU Baeckerei & Konditorei GmbH, which produce and supply its stores with a variety of meats and bakery products, respectively. As of December 31, 2011, the Company operated through 24 affiliated companies and subsidiaries located in Germany. Advisors' Opinion:

• [By Benjamin Pimentel]

  With H-P and JD in the spotlight, the tech-heavy Nasdaq Composite Index (COMP) �rose almost 23 points to close at 4,154. The Morgan Stanley High Tech 35 Index (MSH) �and the Philadelphia Semiconductor Index (SOX) �were up a fraction.

• [By Benjamin Pimentel]

  The Nasdaq Composite Index (COMP) �eked out a 0.1% gain to close at 3,922. The benchmark ended the week down 0.5%. The Morgan Stanley High Tech 35 Index (MSH) �was also up a fraction, while the Philadelphia Semiconductor Index (SOX) �fell 0.3%.

• [By Benjamin Pimentel]

  The Morgan Stanley High Tech 35 Index (MSH) � and the Philadelphia Semiconductor Index (SOX) �were each down a fraction on Friday.

Hot Low Price Companies For 2014: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By Sean Williams]

  Cell Therapeutics (NASDAQ: CTIC  )
  Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

Hot Low Price Companies For 2014: World Acceptance Corp (WRLD)

World Acceptance Corporation operates a small-loan consumer finance business in 12 states and Mexico. The Company is engaged in the small-loan consumer finance business, offering short-term small loans, medium-term larger loans, related credit insurance and ancillary products and services to individuals. As of March 31, 2012, the Company offered standardized installment loans through 1,137 offices in South Carolina, Georgia, Texas, Oklahoma, Louisiana, Tennessee, Illinois, Missouri, New Mexico, Kentucky, Alabama, Wisconsin, and Mexico. The Company serves individuals with limited access to consumer credit from banks, credit unions, other consumer finance businesses and credit card lenders. In the United States offices, the Company also offers income tax return preparation services to its customers and others.

During the fiscal year ended March 31, 2012 (fiscal 2012), the Company opened 69 new offices. In each state in which it operates and in Mexico, the Company offers consumer installment loans, which are standardized by amount and maturity. The Company's loans are consumer installment loans, which are payable in fully amortizing monthly installments with terms generally of 4 to 36 months, and all loans are pre-payable at any time without penalty. During fiscal 2012, the Company's average originated gross loan term was approximately 12 months. As of March 31, 2012, the annual percentage rates on loans offered by the Company, which include interest, fees and other charges as calculated for the purposes of the requirements of the federal Truth in Lending Act, ranged from 24% to 204% depending on the loan size, maturity and the state, in which the loan is made. In addition, in certain states, the Company, as agent for an unaffiliated insurance company, sells credit insurance in connection with its loan transactions.

Specific allowable charges vary by state and, consistent with industry practice, the Company generally charges at or close to the maximum rates allowable under app! licable state law in those states that limit loan rates. Statutes in Texas and Oklahoma allow for indexing the maximum loan amounts to the Consumer Price Index. The Company�� loan products are pre-computed loans in which the finance charge is a combination of origination or acquisition fees, account maintenance fees, monthly account handling fee and other charges permitted by the relevant state laws.

The Company, as an agent for an unaffiliated insurance company, markets and sells credit life, credit accident and health, credit property, and unemployment insurance in connection with its loans in selected states where the sale of such insurance is permitted by law. Credit life insurance provides for the payment in full of the borrower's credit obligation to the lender in the event of death. Credit accident and health insurance provides for repayment of loan installments to the lender, which come due during the insured's period of income interruption resulting from disability from illness or injury. Credit property insurance insures payment of the borrower's credit obligation to the lender in the event, which the personal property pledged as security by the borrower is damaged or destroyed by a covered event. Unemployment insurance provides for repayment of loan installments to the lender, which come due during the insured�� period of involuntary unemployment. The Company requires each customer to obtain specific credit insurance in the amount of the loan for all loans originated in Georgia under the Georgia Industrial Loan Act, and encourages customers to obtain credit insurance for all loans originated in South Carolina, Louisiana, Alabama and Kentucky and on a limited basis in Tennessee, Oklahoma, and Texas. Customers in those states obtain such credit insurance through the Company.

In South Carolina, Georgia, Louisiana, Kentucky and Alabama, the Company charges its borrowers for its non-file premiums in connection with certain loans in lieu of recording and perfecting the! Company� �s security interest in the loan collateral. The premiums are remitted to a third party insurance company for non-file insurance coverage. The Company also markets automobile club memberships to its borrowers in Georgia, Tennessee, New Mexico, Louisiana, Alabama, Texas, and Kentucky as an agent for an unaffiliated automobile club. Club memberships entitle members to automobile breakdown and towing reimbursement and related services. The Company is paid a commission on each membership sold.

The Company offers income tax return preparation and electronic filing. This program is provided in all but a few of the Company�� the United States offices. During fiscal 2012, the Company prepared 44,000 returns. During fiscal 2012, 93.4% of the Company�� revenues were attributable to the United States customers and 6.6% were attributable to customers in Mexico. During fiscal 2012, approximately 84.7% of the Company's loans were generated through refinancings of outstanding loans and the origination of new loans to previous customers.

Advisors' Opinion:

• [By Geoff Gannon]

  1. World Acceptance (WRLD)
  2. Express Scripts (ESRX)
  3. Walgreen (WAG)
  4. Humana (HUM)
  5. McDonald's (MCD)

  Those are the kinds of companies a younger ��and poorer ��Warren Buffett might buy. Actually, a few of those companies are big enough for Warren Buffett to buy today.

• [By Canadian Value]

  So I�� going to stick my next out and share my views on four battleground stocks that are among my favorite shorts: World Acceptance (WRLD), Green Mountain (GMCR), Herbalife (HLF), and InterOil (IOC). And next week at the Value Investing Congress I will present another short, my largest.

• [By Ben Levisohn]

  Shares of World Acceptance Corporation (WRLD) have plunged today after the company disclosed in an 8K that the�Consumer Financial Protection Bureau has requested information about its sales practices.

  Getty Images Consumer Financial Protection Bureau Director Richard Cordray

  Shares of World Acceptance Corporation have plunged 19% to $79.19 at 3:43 p.m.–and dragged down anything remotely connected to payday lending. Cash America International (CSH) has dropped 7.8% to $39.35, pawn-shop operator EZCorp (EZPW) has fallen 3.7% to $12.33, and wire-transfer companies Western Union (WU) and MoneyGram International (MGI) have fallen 2.6% and 5.8%, respectively.

  Sterne Agee’s Henry Coffey and team explain what’s happening with World Acceptance and why they continue to rate it Neutral:

  1. Because of the company’s size (largest or second largest small loan company in the country), it was inevitable that the CFPB would be looking into [World Acceptance]. The question never was “if” in our minds but “when.”

  2. The inquiry does not in itself mean there are issues that have been discovered by the CFPB…

  4. With approximately 30% of the company’s loans underwritten with some form of credit insurance, it would be difficult for�[World Acceptance] to continue to make these loans without this product…

  6. The company indicated in its 8K that it believes it is in compliance with the law.

  Shares of World Acceptance Corporation has dropped 9.2% so far this year, while Cash America International has gained 2.7%, EZCorp has risen 5.5%, Western Union has fallen 6.6% and MoneyGram International has declined 15% in 2014.